Literature DB >> 22357955

Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.

Riikka Pietilä1, Marjut Nätynki, Tuomas Tammela, Jaakko Kangas, Kristina H Pulkki, Nisha Limaye, Miikka Vikkula, Gou Young Koh, Pipsa Saharinen, Kari Alitalo, Lauri Eklund.   

Abstract

Angiopoietin 1 (Ang1) is an activating ligand for the endothelial receptor tyrosine kinase Tie2, whereas Ang2 acts as a context-dependent agonist or antagonist that has a destabilizing effect on the vasculature. The molecular mechanisms responsible for the versatile functions of Ang2 are poorly understood. We show here that Ang2, but not Ang1, induces Tie2 translocation to the specific cell-matrix contact sites located at the distal end of focal adhesions. The Ang2-specific Tie2 translocation was associated with distinct Tie2 activation and downstream signals which differed from those of Ang1, and led to impaired cell motility and weak cell-matrix adhesion. We demonstrate that the different oligomeric or multimeric forms of the angiopoietins induce distinct patterns of Tie2 trafficking; the lower oligomerization state of native Ang2 was crucial for the Ang2-specific Tie2 redistribution, whereas multimeric structures of Ang1 and Ang2 induced similar responses. The Ang2-specific Tie2 trafficking to cell-matrix contacts was also dependent on the cell substratum, α2β1-integrin-containing cell-matrix adhesion sites and intact microtubules. Our data indicate that the different subcellular trafficking of Tie2-Ang2 and Tie2-Ang1 complexes generates ligand-specific responses in the angiopoietin-Tie signaling pathway, including modulation of cell-matrix interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357955     DOI: 10.1242/jcs.098020

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  16 in total

1.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

Review 2.  Receptor tyrosine kinase-mediated angiogenesis.

Authors:  Michael Jeltsch; Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-09-01       Impact factor: 10.005

3.  Angiopoietin-4-dependent venous maturation and fluid drainage in the peripheral retina.

Authors:  Harri Elamaa; Minna Kihlström; Emmi Kapiainen; Mika Kaakinen; Ilkka Miinalainen; Symantas Ragauskas; Marc Cerrada-Gimenez; Satu Mering; Marjut Nätynki; Lauri Eklund
Journal:  Elife       Date:  2018-11-16       Impact factor: 8.140

Review 4.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

5.  Formation of a PKCζ/β-catenin complex in endothelial cells promotes angiopoietin-1-induced collective directional migration and angiogenic sprouting.

Authors:  Malika Oubaha; Michelle I Lin; Yoran Margaron; Dominic Filion; Emily N Price; Leonard I Zon; Jean-François Côté; Jean-Philippe Gratton
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

6.  Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.

Authors:  Veli-Matti Leppänen; Pipsa Saharinen; Kari Alitalo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-10       Impact factor: 11.205

7.  Erythrocytic stage-dependent regulation of oligomerization of Plasmodium ribosomal protein P2.

Authors:  Sudipta Das; Rajagopal Sudarsan; Subramanian Sivakami; Shobhona Sharma
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

8.  Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemia.

Authors:  Léna Marteau; Samuel Valable; Didier Divoux; Simon A Roussel; Omar Touzani; Eric T MacKenzie; Myriam Bernaudin; Edwige Petit
Journal:  J Cereb Blood Flow Metab       Date:  2012-12-05       Impact factor: 6.200

9.  Endothelial destabilization by angiopoietin-2 via integrin β1 activation.

Authors:  Laura Hakanpaa; Tuomas Sipila; Veli-Matti Leppanen; Prson Gautam; Harri Nurmi; Guillaume Jacquemet; Lauri Eklund; Johanna Ivaska; Kari Alitalo; Pipsa Saharinen
Journal:  Nat Commun       Date:  2015-01-30       Impact factor: 14.919

10.  A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Authors:  Markus Thomas; Yvonne Kienast; Werner Scheuer; Monika Bähner; Klaus Kaluza; Christian Gassner; Frank Herting; Ulrich Brinkmann; Stefan Seeber; Anita Kavlie; Martin Welschof; Stefan Ries; K Michael Weidner; Jörg T Regula; Christian Klein
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.